Sera Prognostics Inc

NASDAQ SERA

Download Data

Sera Prognostics Inc Operating Expense Ratio 5 year CAGR for the year ending December 31, 2023

Sera Prognostics Inc Operating Expense Ratio 5 year CAGR is NA for the year ending December 31, 2023. The operating expense ratio represents the proportion of a company's operating expenses to its revenue. It is calculated by dividing the operating expenses by the revenue. This ratio provides insights into the efficiency of a company's cost structure and its ability to control operating expenses relative to its revenue generation. A lower ratio indicates higher operational efficiency and cost management, while a higher ratio suggests higher operating expenses relative to revenue. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Sera Prognostics Inc Operating Expense Ratio for the year ending December 31, 2022 was 17,062.31%, a -60.52% change year over year.
  • Sera Prognostics Inc Operating Expense Ratio for the year ending December 31, 2021 was 43,219.51%, a -39.92% change year over year.
  • Sera Prognostics Inc Operating Expense Ratio for the year ending December 31, 2020 was 71,940.00%, a 56.23% change year over year.
  • Sera Prognostics Inc Operating Expense Ratio for the year ending December 31, 2019 was 46,047.22%.
NASDAQ: SERA

Sera Prognostics Inc

CEO Dr. Gregory C. Critchfield M.D., M.S.
IPO Date July 15, 2021
Location United States
Headquarters 2749 East Parleys Way, Salt Lake City, UT, United States, 84109
Employees 55
Sector Healthcare
Industry Diagnostics & research
Description

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Similar companies

FONR

Fonar Corporation

NA

NA

OLK

Olink Holding AB ADR

NA

NA

XGN

Exagen Inc

NA

NA

DRIO

DarioHealth Corp

NA

NA

PSNL

Personalis Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email